Management of dermatologic adverse events with apalutamide in prostate cancer

“The majority of patients were able to stay on the dose of the apalutamide,” says Mario E. Lacouture, MD.

In this video, Mario E. Lacouture, MD, discusses the background, findings, and takeaways of the Journal of Urology study, “Dermatologic adverse events in prostate cancer patients treated with androgen receptor inhibitor apalutamide.” Lacouture is a dermatologist at Memorial Sloan Kettering Cancer Center in New York, New York.